Flavio G. Rocha, Hedinger Chair of Surgical Oncology and Physician-in-Chief at the OHSU Knight Cancer Institute, shared a post by ESMO Open, on X, adding:
“Applause to the investigators who are expert colleagues in cholangiocarcinoma for trying to complete this important trial.
The challenges highlighted in designing these types of studies in rare cancers are significant and warrant more attention so we can find more options for patients.”
Quoting the post from ESMO Open.
“Ph3 trial of infigratinib vs gem/cis in advanced CCA with FGFR2 fusion/rearrangement: results and reflections on early termination of PROOF 301 in ESMO Open.
48/300 randomized pts in >3yrs.
New frameworks needed to assess therapies in ultra-rare tumors. ”
Title: Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301
Authors: G.K. Abou-Alfa, I. Borbath, S. Roychowdhury, L. Goyal, A. Lamarca, T. Macarulla, R.T. Shroff, D.-Y. Oh, C. Tamaş, D.M. Savastano, D.F. van Veenhuyzen, C. Xu, E. Freas, J. Solanas, M.M. Javle
Other articles featuring Flavio G. Rocha on OncoDaily.
